Diabetes

In this large cohort study spanning nine databases across the USA and Europe, researchers compared 18 safety outcomes across four major classes of second-line antihyperglycaemic agents.

Night shift work in type 2 diabetes is linked to higher glucose variability, increased snacking, and prolonged wakefulness, underscoring the need for tailored care strategies.

The prevalence of incident diabetes increases following COVID-19 infection, a 2026 systematic review and meta-analysis has revealed.

Semaglutide is associated with a lower risk of worsening anxiety, depression, and substance use disorder in patients with co-occurring mental illness and diabetes.

Semaglutide is set to be offered to more than one million people with cardiovascular disease on the NHS in coming months.

Children with metabolically healthy obesity still face increased cardiometabolic risks by adulthood, highlighting the need for early intervention.

Scientists have discovered a previously unknown neural pathway behind the antidiabetic effects of metformin, a standard first-line treatment for Type 2 diabetes.

Discontinuation of, or interruptions to, GLP-1 treatment may increase the risk of major adverse cardiovascular events in adults with Type 2 diabetes.